Acadia Pharmaceuticals INC

Acadia Pharmaceuticals stockholders approved an increase of 5,209,670 shares for the 2024 Equity Incentive Plan and elected three Class I directors.

Acadia Pharmaceuticals reported $268 million in Q1 2026 revenue, driven by strong DAYBUE sales and reaffirmed full-year guidance.

Acadia Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, surpassing $1 billion in annual revenue for the first time, driven by NUPLAZID and DAYBUE sales.

Acadia Pharmaceuticals Inc. announced at the J.P. Morgan Healthcare Conference that it anticipates 2025 net sales will exceed $1 billion, aligning with previous guidance.

Acadia Pharmaceuticals announced robust third-quarter 2025 financial results, exceeding $1 billion in year-to-date sales and raising full-year revenue guidance.

Acadia Pharmaceuticals Inc. announced the resignation of Daniel B. Soland from its Board of Directors and Nominating and Corporate Governance Committee, effective October 30, 2025.

Acadia Pharmaceuticals reported robust product sales growth and significant net income increase in Q3 2025, driven by NUPLAZID and DAYBUE, while discontinuing a Phase 3 PWS program.

Acadia Pharmaceuticals reported increased product sales for Q2 2025 driven by NUPLAZID and DAYBUE, while net income declined due to higher operating expenses and tax liabilities, as the company advances its pipeline and navigates ongoing legal challenges.

Acadia Pharmaceuticals announces Q1 2025 financial results, highlighting revenue growth driven by increased sales of NUPLAZID and DAYBUE.

Acadia Pharmaceuticals saw revenue growth in Q3 2024, driven by increased sales of both NUPLAZID and DAYBUE, while also managing research and development expenses.

Acadia Pharmaceuticals reported a profitable second quarter of 2024, driven by significant revenue growth from both NUPLAZID and DAYBUE.

Acadia Pharmaceuticals saw a significant increase in revenue in the first quarter of 2024, driven by sales of both NUPLAZID and DAYBUE.

Acadia Pharmaceuticals reported net product sales of $1.07 billion in 2025, driven by growth in NUPLAZID and DAYBUE, despite a negative trend vote for DAYBUE's EU approval.

Acadia Pharmaceuticals' 10-K filing summarizes the company's 2024 performance, strategic initiatives, and key risks.

Acadia Pharmaceuticals Inc. demonstrates significant progress in 2023 with increased product sales and advancements in its clinical pipeline, as detailed in its annual 10-K filing.

Mark C. Schneyer, EVP, CHIEF FINANCIAL OFFICER of Acadia Pharmaceuticals Inc, sold 20,141 shares of common stock on August 5, 2026.

Elizabeth H.Z. Thompson, EVP, Head of Research & Dev of Acadia Pharmaceuticals Inc, sold 16,558 shares of common stock on July 29, 2026.

James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, reported a sale of common stock under a Rule 10b5-1 trading plan.

Baker Bros. Advisors LP, a significant holder, has reported changes in beneficial ownership of Acadia Pharmaceuticals Inc. common stock and stock options.

Director Edmund Harrigan acquired 8,107 shares of Acadia Pharmaceuticals common stock through the vesting of restricted stock units.

Director Adora Ndu exercised restricted stock units and received new equity grants as part of Acadia Pharmaceuticals' annual compensation cycle.

Acadia Pharmaceuticals has released its proxy statement for the 2025 Annual Meeting of Stockholders, detailing director elections, executive compensation, and auditor ratification.

Acadia Pharmaceuticals' 2024 proxy statement details executive compensation, board structure, and key proposals for the upcoming annual meeting.

Baker Bros. Advisors and its affiliates have updated their significant beneficial ownership in ACADIA Pharmaceuticals Inc. and secured new registration rights for their securities.

State Street Corporation has updated its beneficial ownership filing for Acadia Pharmaceuticals Inc., reporting a significant holding of common stock.

Vanguard Portfolio Management has reported beneficial ownership of over 8.78 million shares, representing 5.15% of Acadia Pharmaceuticals Inc.'s common stock.

The Vanguard Group has reported 0% beneficial ownership in ACADIA Pharmaceuticals Inc. following an internal realignment where subsidiaries will now report separately.

RTW Investments and Roderick Wong reported a reduced beneficial ownership of 4.2% in Acadia Pharmaceuticals Inc. common stock.

Investment firm RTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have disclosed a beneficial ownership of 5.2% in Acadia Pharmaceuticals Inc., totaling 8,705,501 shares.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a significant 11.9% beneficial ownership stake in Acadia Pharmaceuticals Inc. as of January 31, 2025.